Zhongheng Cai

Dr. Zhongheng Cai

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Statistics and Its Interface
Verified
Journal Article
Closed access
PDF file
ZCZhongheng Cai
Zhongheng Cai
DSDongchu Sun
Dongchu Sun

6 July 2021 in Statistical Theory and Related Fields
Verified
Journal Article
Closed access
ZCZhongheng Cai
Zhongheng Cai
DSDongchu Sun
Dongchu Sun
In Bayesian quantile smoothing spline [Thompson, P., Cai, Y., Moyeed, R., Reeve, D., & Stander, J. (2010). Bayesian nonparametric quantile regression using splines. Computational Statistics and Data Analysis, 54, 1138–1150.], a fixed-scale parameter in the asymmetric Laplace likelihood tends to result in misleading fitted curves. To solve this problem, we propose a new Bayesian quantile smoothing spline (NBQSS), which considers a random scale parameter. To begin with, we justify its objective prior options by establishing one sufficient and one necessary condition of the posterior propriety under two classes of general priors including the invariant prior for the scale component. We then develop partially collapsed Gibbs sampling to facilitate the computation. Out of a practical concern, we extend the theoretical results to NBQSS with unobserved knots. Finally, simulation studies and two real data analyses reveal three main findings. Firstly, NBQSS usually outperforms other competing curve fitting methods. Secondly, NBQSS considering unobserved knots behaves better than the NBQSS without unobserved knots in terms of estimation accuracy and precision. Thirdly, NBQSS is robust to possible outliers and could provide accurate estimation.

22 July 2026 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
ESElizabeth Seewer
Elizabeth Seewer
SWSarah Williams
Sarah Williams
SHSara Tyson Husband
Sara Tyson Husband
ABAmanda Brown
Amanda Brown
MSMohammad Sabobeh
Mohammad Sabobeh
SGSaad Ghafoor
Saad Ghafoor
Background/Objectives: Children with cancer admitted to the pediatric intensive care unit (PICU) are at increased risk for post-intensive care syndrome (PICS-p) due to prolonged immobility, deep sedation, and severe illness. The ABCDEF bundle offers a framework for enhancing ICU care and patient recovery, but implementing all components in pediatric oncology patients is challenging. This study assesses the development and implementation of the BRAVE (Beginning Restorative Activities Very Early) initiative, specifically BRAVE2, to integrate the comprehensive ABCDEF bundle and a nurse-led mobility program, in collaboration with rehabilitation specialists, within a pediatric oncology intensive care unit. Methods: BRAVE2 was a quality improvement project conducted in a single pediatric ICU from 2022 to 2023. We analyzed ICU data to assess patient demographics, frequency of physical and occupational therapy (PT/OT) consultations, time to initial mobilization, and delirium screening rates (CAPD score of 9 or higher) for patients with ICU stays over 48 h. BRAVE2 addressed all elements of the ABCDEF bundle, including regular pain assessments, evaluation of spontaneous breathing readiness, sedation adjustments, delirium screening, early mobilization, and family engagement. Outcomes were monitored using statistical process control methods. Results: Of 140 patients, 117 (84%) remained in the ICU for more than 48 h. The delirium screening rate was 15.5%, consistently below the target of 30%. PT/OT consultations within 72 h occurred in 80.7% of patients, and early mobilization in 49.7% of patients, both below the 80% goal. However, 90.4% of patients with tracked mobility were able to ambulate during their ICU stay. No mobility-related safety incidents were reported. Conclusions: Rolling out a full ICU liberation plan in a pediatric oncology ICU is possible, and implementing a comprehensive one is feasible and sustainable despite challenges. Although therapist-led early mobilization did not meet targets, incorporating nurse-led mobility strategies and routine delirium screening has established a scalable model to enhance ICU care and support long-term recovery for these patients.

30 April 2026
Verified
Book Chapter
Closed access
PDF file
ZCZhongheng Cai
Zhongheng Cai
HPHaitao Pan
Haitao Pan
CHChia-Wei Hsu
Chia-Wei Hsu
JWJianrong Wu
Jianrong Wu
JYJingjing Ye
Jingjing Ye
The objective of this chapter is to introduce screening selection designs for master protocol pediatric oncology trials with binary and time-to-event endpoints. We will specifically focus on two St. Jude pediatric oncology trials: one in pediatric neuroblastoma and the other in pediatric Ewing sarcoma. The chapter will discuss the methodology and implementation of screening selection designs using the R package frequentistSSDBinary for binary endpoint and frequentistSSD for time-to-event endpoint.

25 September 2023 in Communications in Statistics - Theory and Methods
Verified
Journal Article
Closed access
QWQiao Wang
Qiao Wang
ZCZhongheng Cai
Zhongheng Cai

3 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JGJessica Gartrell
Jessica Gartrell
FNFariba Navid
Fariba Navid
XYXiaomeng Yuan
Xiaomeng Yuan
KNKirsten K. Ness
Kirsten K. Ness
MDMikhail Doubrovin
Mikhail Doubrovin
SFsara federico
sara federico
Study Aim: Patients with high-risk Ewing sarcoma (ES) have dismal outcomes despite aggressive multimodal therapy. This phase II, single-institution study evaluated the response rate to two up-front cycles of irinotecan, temozolomide, and temsirolimus (ITT) and assessed the tolerability of maintenance therapy following standard treatment in high-risk ES. Methods: Eligible patients had newly diagnosed high-risk ES (age ≥14 years old, metastatic disease, or primary pelvic tumor). The therapy included two cycles of window therapy (ITT) followed by interval-compressed chemotherapy (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide) and maintenance therapy (cyclophosphamide, sorafenib, and bevacizumab). A two-stage sequential design was employed to assess a >50% WHO response (CR or PR) with 80% power. Patients who required emergent radiation were excluded from receiving window therapy. Results: Sixteen patients (median age 12.2 years; range 4.8–23.6 years) were enrolled (12 evaluable for overall response, 10 for primary tumor response). Only three achieved a PR to window therapy, leading to study closure. All evaluable patients demonstrated a decline in their primary tumor volume (mean decline: 32.5%, standard deviation: 17.6%, p-value: 0.0005) and SUV peak (mean decline: 49.9%, standard deviation: 21.1%, p-value: 0.002). Maintenance therapy was well tolerated, with only 2/13 patients discontinuing due to toxicity. Conclusions: ITT did not achieve the prespecified response rate of 50%, according to WHO criteria; however, all patients exhibited decreased volume and metabolic activity, highlighting the limitations of conventional response assessments. Maintenance therapy was feasible and well tolerated. Although limited by small sample size, heterogeneous disease presentations, and the absence of a control arm, this study supports further evaluation of ITT and a maintenance approach in larger, randomized trials for high-risk ES.